GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operatio...(s. Other highlights of the presentation ...)

included:

o GeoVax vaccines were well tolerated with no or mild local and

systemic reactions in the majority of trial participants.

o 80 percent of both the low and full dose trial participants

responded to the vaccine which stimulated anti-HIV T-cell

(white blood cell) and antibody responses.

o More volunteers had antibody responses to the full dose than to

the 1/10th dose vaccine, whereas response rates for T cells

were similar for the 1/10th and full dose.

o Two DNA primes were more effective than one DNA prime or no DNA

primes at eliciting T cell responses.

o The 2nd MVA vaccination positively increased CD8 T cell and

antibody responses.

Dr. Harriet Robinson, the developer of the vaccine and GeoVax's Vice President of Research and Development, also presented these same results at the Viral Vector Vaccines 2008 meeting, at the Wellcome Trust Conference Center near Cambridge, UK, on September 28, 2008.

* In August 2008, GeoVax announced the appointment of Mr. Peter

Tsolinas to its Board of Directors. Mr. Tsolinas also was

subsequently appointed to membership on GeoVax's Audit Committee and

Compensation Committee. Mr. Tsolinas currently serves as Chairman

and CEO of TMA Group Development Corp., a Chicago-based real estate,

architectural and development firm.

* In July 2008, GeoVax and Vivalis S.A., a French biopharmaceutical

company that provides innovative cell-based solutions to the

pharmaceutical industry for the manufacture of vaccines and

proteins, jointly announced the signing of a letter of intent for

joint collaboration and commercial license on the use of Vivalis'

'/>"/>